focus -WSS

focus

author：explore 2025-08-23 23:20:13 - browse：7

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Hospitals need to get ahead of regulations on climate change

WSS

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Congress: Prevent baby formula shortages by passing a new bill

Canadians with cystic fibrosis outlive Americans by a decade

Asahi Kasei to buy Calliditas, picking up kidney disease drug

The biotech scorecard for Q3: 15 stock

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

hotspot

focus

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Beware reading your test results before your doctor does

Jerome Adams on the need for new antivirals for Covid

Lawsuit challenges CMS nursing home minimum staffing rule

Psychedelics group wrestles with new pharma identity

Pharma’s losing bet in New Jersey

Apple is now the first public company to be valued at $3 trillion

Crowdfunding for unproven stem cell procedures spreads misinformation

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ozempic cut risk of death in diabetes patients with chronic kidney disease

hotspot

'Screen and refer' systems are hurting patients

Lupron, used to halt puberty in children, may cause lasting health problems

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Unmasking the 'centricity' illusion in clinical trials

Medical students need to learn the potent medicine of empathy

hotspot

knowledge

focus

hotspot